For years, Kasia Lipska, MD, MHS, associate professor of medicine (endocrinology) at Yale School of Medicine (YSM), has been ...
Weights, aerobics, and … Wegovy? Some in the fitness industry are moving to dispense the popular GLP-1 medications to club ...
The North Carolina state treasurer is taking on drugmakers Novo Nordisk and Eli Lilly in an attempt to lower drug costs for ...
As the treatment of obesity in the 21st century takes a monumental turn, the need for quality care is more pressing than ever: Tips for starting a new obesity-focused practice.
Drugmakers are preparing to launch an estimated 13 new weight-loss treatments in the U.S. over the next five years, according ...
Roche Joins Race for Obesity Drugs With $2.7 Billion Carmot Deal Roche agreed to take over unlisted obesity drug developer Carmot Therapeutics for $2.7 billion upfront, joining a list of ...
Even if they're not acquired, these small companies are developing promising obesity and diabetes treatments A couple of big-picture trends in biotech could add up to a nice investment opportunity.
A budget-busting 3.6 million Medicare recipients could now be eligible for coverage of the weight-loss drug Wegovy, a new KFF ...
LONDON — Following a nine-month investigation, European regulators said Friday they have found no evidence that GLP-1 drugs like Ozempic and Wegovy cause suicidal thoughts or actions. The ...
Share on Facebook. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Twinamatsiko and Ranganathan are experts in health law and ...
People with obesity-related heart failure and diabetes can get substantial heart-health benefits from the popular obesity drug Wegovy, even if they don’t shed a lot of weight on the medication ...
Heart-failure patients with diabetes may shed fewer pounds on Wegovy but still get cardiovascular benefit, research finds People with obesity-related heart failure and diabetes can get substantial ...